– Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral* and PecFent* for breakthrough cancer pain, Moventig* for opioid-induced constipation, and Adcal-D3* for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide. «Grünenthal is a global leader in pain management.